Loading Events

Bringing together both the scientific and the pharmaceutical communities, this Keystone Symposia meeting will will focus on:

1) The newest findings on the mechanisms by which epigenetic pathways are established and maintained in normal and stem cells, and how these go awry during aging and cancer, with a special emphasis on histone modifications, chromatin remodeling and the unexpected increased number of DNA modifications ((hydroxy)methylcytosine and methyladenine);

2) The growing roles of noncoding RNAs in cancer and the emergence of the new and exciting realm of RNA epigenetics;

3) Use of new omics technologies to interrogate altered epigenetic landscapes in tumors and assess their clinical implications;

4) Novel and promising therapeutic drugs aimed at reversing specific epigenetic alterations. Ultimately, the meeting will provide great opportunities for senior and junior scientists to meet the leaders in the field from both academia and industry, hence forging exciting interdisciplinary interactions and creating potential new collaborations in the booming area of cancer epigenetics.

Invited Speakers:

Karen Adelman, Harvard Medical School, USA

Geneviève Almouzni, Centre National de la Recherche Scientifique, France

Stephen B. Baylin, Johns Hopkins University School of Medicine, USA

Aznar Benitah, ICREA and Institute for Research in Biomedicine, Spain

Shelley L. Berger, University of Pennsylvania, USA

James E. Bradner, Novartis Institutes for BioMedical Research, USA

Anne Brunet, Stanford University, USA

Howard Y. Chang, Stanford University, USA

Mark A. Dawson, Peter MacCallum Cancer Centre, Australia

Luciano Di CroceCentre for Genomic Regulation, Spain

Michaela Frye, University of Cambridge, UK

François Fuks, Université Libre De Bruxelles, Belgium

Chuan He, University of Chicago, USA

Peter A. Jones, Van Andel Research Institute, USA

Cigall Kadoch, Dana-Farber Cancer Institute, Harvard Medical School, USA

Tony Kauzarides, University of Cambridge, UK

Electron Kebebew, National Cancer Institute, USA

Robert E. Kingston, Massachusetts General Hospital, USA

Robert MacLeod, Ionis Pharmaceuticals, Inc., USA

Chris Marine, VIB, Belgium

Robert A. Martienssen, Cold Spring Harbor Laboratory, USA

Ronan C. O’Hagan, Merck Research Laboratories, USA

Kornelia Polyak, Dana-Farber Cancer Institute, Harvard Medical School, USA

Rab K. Prinjha, GlaxoSmithKline, UK

Gideon Rechavi, Tel Aviv University, Israel

Danny F. Reinberg, HHMI/New York University, USA

Ali Shilatifard, Northwestern University, USA



Scholarship Deadline: Oct 10, 2017 
Discounted Abstract Deadline: Oct 10, 2017 
Abstract Deadline: Nov 8, 2017 
Discounted Registration Deadline: Dec 12, 2017 

Scientific Organizers: François Fuks and Anne Brunet